NCCP 00525 · clinician draft
Ribociclib + endocrine therapy · metastatic
Select a phase to see its script. Only one phase is shown or printed at a time.
Ribociclib + endocrine therapy · metastatic · supportive-care plan
Download this phase PDF · Open printable script
Active medicines: Ribociclib + AI or fulvestrant
Emetogenic risk: Oral moderate–high
No routine prophylactic antiemetic order is populated for this phase. Agree an individual symptom-treatment plan where needed.
Additional phase-specific support
- NCCP classifies ribociclib as oral moderate–high emetic risk. The team chooses preventive or rescue antiemetics using local policy, symptoms, QT risk and drug interactions; do not reuse another regimen’s prescription.
- Correct abnormal potassium, calcium, magnesium and phosphate as directed. Attend the baseline and cycle 1 Day-14 ECG; fainting or palpitations need urgent advice.
- Keep the early two-weekly blood tests and subsequent monitoring. Report fever, shivers, jaundice or dark urine promptly.
- The AI or fulvestrant, and ovarian suppression when prescribed, continue on their own timetable. Discuss joint, menopausal, bone and injection-site symptoms.
- Avoid grapefruit and check interactions. Do not replace a missed or vomited dose. A clinical hold requires explicit instructions about which medicine stops and who authorises restart.
Before signing: verify allergies, current medicines, interactions, renal / hepatic function, QT risk, sedation, prior response, total steroid exposure and the rescue-medicine duration. Do not duplicate medicines from another phase.
Individual changes / rescue duration: __________________________________
Prescriber / date: __________________ Pharmacy review: __________________
Sources checked 2026-10-25 · SACTCheck v0.84.21 · Regimen-level drafts; prescriber and oncology-pharmacy verification required